Randomized Clinical Trial of the Effectiveness of a Home-Based Advanced Practice Psychiatric Nurse Intervention: Outcomes for Individuals with Serious Mental Illness and HIV
Table 4
Health-related quality outcomes: average treatment effects for patients receiving advanced practice registered nurse intervention, by dose, versus usual care.
APRN dose
Period
Effect ()
95% CI
Effect ()
95% CI
Effect ()
95% CI
Effect (d)
95% CI
Effect ()
95% CI
Mental composite
Physical Composite
Mental health
General health
Social functioning
Low
Baseline to 3 M
1.25
−1.7, 4.2
.42
−0.55
−3.7, 2.6
.73
0.19
−0.2, 0.6
.40
−0.01
−0.4, 0.4
.94
−0.01
−0.5, 0.5
.94
3 M to 6 M
0.59
−2.5, 3.6
.70
−1.75
−4.9, 1.4
.27
0.01
−0.4, 0.4
.95
−0.10
−0.6, 0.4
.67
−0.12
−0.7, 0.4
.65
6 M to 12 M
0.84
−2.5, 4.1
.61
0.44
−3.1, 3.9
.80
0.19
−0.2, 0.6
.43
−0.15
−0.6, 0.4
.55
0.01
−0.5, 0.6
.97
Baseline to 12 M
2.99
−0.2, 6.2
.07
−3.60
−7.3, 0.1
.05
0.56
0.4, 0.6
.76
−0.19
−0.7, 0.3
.47
0.12
−0.5, 0.7
.70
Moderate
Baseline to 3 M
0.57
−2.4, 3.5
.71
−0.11
−3.3, 3.0
.94
0.01
−0.4, 0.4
.98
0.15
−0.3, 0.6
.50
0.03
−0.5, 0.5
.94
3 M to 6 M
0.90
−1.9, 3.7
.53
−1.12
−
4.0, 1.8
.45
−0.13
−0.5, 0.3
.54
−0.07
−0.5, 0.4
.75
−0.04
−0.5, 0.4
.88
6 M to 12 M
1.46
−2.4, 5.3
.47
0.75
−3.3, 4.8
.71
0.27
−0.3, 0.8
.35
−0.12
−0.7, 0.5
.68
0.05
−0.6, 0.7
.88
Baseline to 12 M
2.23
−0.8, 5.3
.15
0.16
−3.3, 3.6
.92
0.27
−0.2, 0.7
.27
−0.02
−0.5, 0.5
.95
−0.01
−0.6, 0.5
.94
High
Baseline to 3 M
−0.57
−2.9, 1.8
.64
1.90
−0.6, 4.4
.14
0.29
−0.1, 0.6
.12
0.45
0.1, 0.8
.02
−0.13
−0.6, 0.3
.54
3 M to 6 M
5.55
1.4, 9.6
.01
−4.14
−8.3, 0.03
.05
0.46
−0.1, 1.0
.13
0.06
−0.6, 0.7
.85
0.35
−0.4, 1.1
.34
6 M to 12 M
1.46
−2.8, 5.8
.50
2.90
−1.7, 7.5
.21
0.27
−0.3, 0.9
.39
−0.01
−07, 0.7
.97
−0.21
−0.9, 0.5
.57
Baseline to 12 M
1.87
−0.8, 4.5
.17
2.60
−0.4, 5.6
.09
0.56
0.1, 0.9
.01
0.55
0.1, 1.0
.01
−0.37
−0.9, 0.1
.16
Vitality
Role activities
Physical role
Bodily pain
Physical functioning
Low
Baseline to 3 M
0.10
−0.3, 0.5
.65
−0.02
−0.5, 0.4
.93
−0.15
−0.6, 0.3
.55
0.04
−0.3, 0.4
.82
0.12
−0.2, 0.4
.52
3 M to 6 M
0.03
−0.4, 0.4
.87
0.03
−0.4, 0.4
.86
−0.02
−0.6, 0.5
.93
−0.12
−0.4, 0.2
.51
−0.26
−0.6, 0.1
.14
6 M to 12 M
0.02
−0.4, 0.4
.92
0.12
−0.2, 0.5
.52
0.17
−0.3, 0.7
.49
0.18
−0.2, 0.5
.37
0.04
−0.3, 0.4
.83
Baseline to 12 M
0.06
−0.4, 0.5
.79
0.21
−0.3, 0.7
.40
−0.38
−0.9, 0.1
.15
0.00
−0.4, 0.4
.98
−0.27
−0.7, 0.1
.16
Moderate
Baseline to 3 M
−0.12
−0.6, 0.3
.59
0.17
−0.3, 0.6
.46
−0.11
−0.6, 0.4
.65
0.08
−0.3, 0.4
.68
0.03
−0.3, 0.4
.85
3 M to 6 M
0.15
−0.2, 0.5
.42
0.20
−0.1, 0.5
.23
−0.08
−0.6, 0.4
.74
−0.16
−0.5, 0.1
.35
−0.02
−0.3, 0.3
.93
6 M to 12 M
−0.09
−0.6, 0.4
.73
0.23
−0.2, 0.7
.29
0.03
−0.5, 0.6
.92
0.42
−0.04, 0.9
.07
0.19
−0.3, 0.6
.40
Baseline to 12 M
−0.16
−0.6, 0.3
.45
0.48
0.03, 0.9
.04
0.20
−0.3, 0.7
.43
0.38
−0.05, 0.8
.08
−0.08
−0.4, 0.3
.66
High
Baseline to 3 M
−0.26
−0.6, 0.1
.15
−0.14
−0.5, 0.2
.46
−0.05
−0.4, 0.3
.79
0.35
0.02, 0.6
.03
0.10
−0.2, 0.4
.46
3 M to 6 M
−0.35
−0.9, 0.2
.19
0.51
0.04, 0.9
.03
0.01
−0.7, 0.7
.99
−0.35
−0.8, 0.1
.14
−0.31
−0.8, 0.2
.18
6 M to 12 M
0.06
−0.5, 0.6
.83
0.63
0.1, 1.1
.01
0.37
−0.3, 1.0
.25
0.65
0.1, 1.1
.01
0.30
−0.2, 0.8
.22
Baseline to 12 M
−0.36
−0.7, −0.01
.05
0.57
0.2, 0.9
.01
0.24
−0.2, 0.7
.27
0.57
0.18, 0.9
.00
−0.23
−0.1, 0.5
.15
Note: Health-related quality of life was measured with the medical outcomes study 12-item short form health survey. Positive effect values indicate improvement.
